Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

Isis Pharmaceuticals, Inc. (ISIS)

-NasdaqGS
32.99 0.19(0.57%) Apr 15, 4:00PM EDT
|After Hours : 33.37 Up 0.38 (1.15%) Apr 15, 4:24PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
United States - Map
Phone: 760-931-9200
Website: http://www.isispharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:365

Business Summary 

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Isis Pharmaceuticals, Inc.

Corporate Governance 
Isis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 6. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 5; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Stanley T. Crooke M.D., Ph.D., 69
Founder, Exec. Chairman, Chief Exec. Officer, Pres and Member of Non-Management Stock Option Committee
1.12M1.59M
Ms. B. Lynne Parshall Esq., J.D., 60
Chief Operating Officer, Corp. Sec. and Director
920.00K688.00K
Dr. C. Frank Bennett BSc, Ph.D., 57
Sr. VP of Antisense Research
567.00K106.00K
Dr. Richard S. Geary Ph.D., 56
Sr. VP of Devel.
558.00K73.00K
Mr. Brett P. Monia Ph.D., 53
Sr. VP of Drug Discovery & Corp. Devel.
546.00K120.00K
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders